|
1.
|
Tsao AS, Wistuba I, Roth JA and Kindler
HL: Malignant pleural mesothelioma. J Clin Oncol. 27:2081–2090.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Sugarbaker DJ, Flores RM, Jaklitsch MT, et
al: Resection margins, extrapleural nodal status, and cell type
determine postoperative long-term survival in trimodality therapy
of malignant pleural mesothelioma: results in 183 patients. J
Thorac Cardiovasc Surg. 117:54–63. 1999. View Article : Google Scholar
|
|
3.
|
Krug LM, Pass HI, Rusch VW, et al:
Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin
followed by extrapleural pneumonectomy and radiation for malignant
pleural mesothelioma. J Clin Oncol. 27:3007–3013. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Van Schil PE, Baas P, Gaafar R, et al:
Trimodality therapy for malignant pleural mesothelioma: results
from an EORTC phase II multicentre trial. Eur Respir J.
36:1362–1369. 2010.PubMed/NCBI
|
|
5.
|
Bonfrer JM, Schouwink JH, Korse CM and
Baas P: Cyfra 21-1 and TPA as markers in malignant mesothelioma.
Anticancer Res. 17:2971–2973. 1997.PubMed/NCBI
|
|
6.
|
Schouwink J, Korse CM, Bonfrer JM, Hart AA
and Baas P: Prognostic value of the serum tumour markers Cyfra 21-1
and tissue polypeptide antigen in malignant mesothelioma. Lung
Cancer. 25:25–32. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Paganuzzi M, Onetto M, Marroni P, et al:
Diagnostic value of CYFRA 21-1 tumor marker and CEA in pleural
effusion due to mesothelioma. Chest. 119:1138–1142. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Hedman M, Arnberg H, Wernlund J, Riska H
and Brodin O: Tissue polypeptide antigen (TPA), hyaluronan and CA
125 as serum markers in malignant mesothelioma. Anticancer Res.
23:531–536. 2003.PubMed/NCBI
|
|
9.
|
Creaney J, van Bruggen I, Hof M, et al:
Combined CA125 and mesothelin levels for the diagnosis of malignant
mesothelioma. Chest. 132:1239–1246. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Pass HI, Lott D, Lonardo F, et al:
Asbestos exposure, pleural mesothelioma, and serum osteopontin
levels. N Engl J Med. 353:1564–1573. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Grigoriu BD, Scherpereel A, Devos P, et
al: Utility of osteopontin and serum mesothelin in malignant
pleural mesothelioma diagnosis and prognosis assessment. Clin
Cancer Res. 13:2928–2935. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Creaney J, Yeoman D, Demelker Y, et al:
Comparison of osteopontin, megakaryocyte potentiating factor, and
mesothelin proteins as markers in the serum of patients with
malignant mesothelioma. J Thorac Oncol. 3:851–857. 2008. View Article : Google Scholar
|
|
13.
|
Rai AJ, Flores RM, Mathew A, et al:
Soluble mesothelin related peptides (SMRP) and osteopontin as
protein biomarkers for malignant mesothelioma: analytical
validation of ELISA based assays and characterization at mRNA and
protein levels. Clin Chem Lab Med. 48:271–278. 2010.
|
|
14.
|
Creaney J, Yeoman D, Musk AW, de Klerk N,
Skates SJ and Robinson BW: Plasma versus serum levels of
osteopontin and mesothelin in patients with malignant mesothelioma
- which is best? Lung Cancer. 74:55–60. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Cristaudo A, Bonotti A, Simonini S, et al:
Combined serum mesothelin and plasma osteopontin measurements in
malignant pleural mesothelioma. J Thorac Oncol. 6:1587–1593. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Hassan R, Bera T and Pasten I: Mesothelin:
a new target for immunotherapy. Clin Cancer Res. 10:3937–3942.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Ray M and Kindler HL: Malignant pleural
mesothelioma: an update on biomarkers and treatment. Chest.
136:888–896. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Hollevoet K, Nackaerts K, Thimpont J, et
al: Diagnostic performance of soluble mesothelin and megakaryocyte
potentiating factor in mesothelioma. Am J Respir Crit Care Med.
181:620–625. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Cristaudo A, Bonotti A, Simonini S, Bruno
R and Foddis R: Soluble markers for diagnosis of malignant pleural
mesothelioma. Biomark Med. 5:261–273. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Hollevoet K, Reitsma JB, Creaney J, et al:
Serum mesothelin for diagnosing malignant pleural mesothelioma: an
individual patient data meta-analysis. J Clin Oncol. 30:1541–1549.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
van der Bij S, Schaake E, Koffijberg H,
Burgers JA, de Mol BA and Moons KG: Markers for the non-invasive
diagnosis of mesothelioma: a systematic review. Br J Cancer.
104:1325–1333. 2011.PubMed/NCBI
|
|
22.
|
Schorge JO, Drake RD, Lee H, et al:
Osteopontin as an adjunct to CA125 in determining recurrent ovarian
cancer. Clin Cancer Res. 10:3474–3478. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Etzioni R, Falcon S, Gann PH, Kooperberg
CL, Penson DF and Stampfer MJ: Prostate-specific antigen and free
prostate-specific antigen in the early detection of prostate
cancer: do combination tests improve detection? Cancer Epidemiol
Biomarkers Prev. 13:1640–1645. 2004.PubMed/NCBI
|
|
24.
|
Travis WD, Brambilla E, Müller-Hermelink
HK and Harris CC: World Health Organization Classification of
Tumors, Pathology and Genetics. Tumours of the Lung, Pleura,
Thymus, and Heart. IARC Press; Lyon: 2004
|
|
25.
|
Husain A, Colby T, Ordonez N, et al:
Guidelines for pathologic diagnosis of malignant mesothelioma: a
consensus statement from the International Mesothelioma Interest
Group. Arch Pathol Lab Med. 133:1317–1331. 2009.PubMed/NCBI
|
|
26.
|
DeLong ER, DeLong DM and Clarke-Pearson
DL: Comparing the areas under two or more correlated receiver
operating characteristics curves: a nonparametric approach.
Biometrics. 44:837–845. 1988. View
Article : Google Scholar
|
|
27.
|
Beyer HL, Geschwindt RD, Glover CL, et al:
Mesomark: a potential test for malignant pleural mesothelioma. Clin
Chem. 53:666–672. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Weber DG, Taeger D, Pesch B, Kraus T,
Brüning T and Johnen G: Soluble mesothelin-related peptides
(SMRP)-high stability of a potential tumor marker for mesothelioma.
Cancer Biomark. 3:287–292. 2007.PubMed/NCBI
|
|
29.
|
Scherpereel A, Grigoriu B, Conti M, et al:
Soluble mesothelin-related peptides in the diagnosis of malignant
pleural mesothelioma. Am J Respir Crit Care Med. 173:1155–1160.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Cristaudo A, Foddis R, Vivaldi A, et al:
Clinical significance of serum mesothelin in patients with
mesothelioma and lung cancer. Clin Cancer Res. 13:5076–5081. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Amati M, Tomasetti M, Scartozzi M, et al:
Profiling tumor-associated markers for early detection of malignant
mesothelioma: an epidemiologic study. Cancer Epidemiol Biomarkers
Prev. 17:163–170. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Pass HI, Wali A, Tang N, et al: Soluble
mesothelin-related peptide level elevation in mesothelioma serum
and pleural effusions. Ann Thorac Surg. 85:265–272. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Schneider J, Hoffmann H, Dienemann H,
Herth FJ, Meister M and Muley T: Diagnostic and prognostic value of
soluble mesothelin-related proteins in patients with malignant
pleural mesothelioma in comparison with benign asbestosis and lung
cancer. J Thorac Oncol. 3:1317–1324. 2008. View Article : Google Scholar
|
|
34.
|
van den Heuvel MM, Korse CM, Bonfrer JM
and Baas P: Non-invasive diagnosis of pleural malignancies: the
role of tumour markers. Lung Cancer. 59:350–354. 2008.PubMed/NCBI
|
|
35.
|
Rodriguez Portal JA, Rodriguez Becerra E,
Rodriguez Rodriguez D, et al: Serum levels of soluble
mesothelin-related peptides in malignant and nonmalignant
asbestos-related pleural disease: relation with past asbestos
exposure. Cancer Epidemiol Biomarkers Prev. 18:646–650. 2009.
|
|
36.
|
Robinson BW, Creaney J, Lake R, et al:
Mesothelin-family proteins and diagnosis of mesothelioma. Lancet.
362:1612–1616. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Ordonez NG: The immunohistochemical
diagnosis of mesothelioma: a comparative study of epithelioid
mesothelioma and lung adenocarcinoma. Am J Surg Pathol.
27:1031–1051. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Ordonez NG: Application of mesothelin
immunostaining in tumor diagnosis. Am J Surg Pathol. 27:1418–1428.
2003. View Article : Google Scholar : PubMed/NCBI
|
